Guggenheim Reiterates Buy Rating on Bristol-Myers Squibb Company PFD CONV 2 (BMYMP)
Rating Change Guggenheim analysts reiterated a Buy rating on Bristol-Myers Squibb Company PFD CONV 2 (OTC:BMYMP) on July 31, 2026. Market Context Bristol-Myers Squibb Company PFD…
Read more
